15795-64-9

Basic information

• Product Name: 4-hydroxy-2,3,6-trimethoxy-5H-benzo[7]annulen-5-one
• Synonyms: 4-Hydroxy-2,3,6-trimethoxy-5H-benzo[a]cyclohepten-5-one; 4-Hydroxy-2,3,6-trimethoxy-benzocyclohepten-5-one
• CAS NO: 15795-64-9
• Molecular Formula: C₁₄H₁₄O₅
• Molecular Weight: 262.258
• Mol File: 15795-64-9.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 503.9°C at 760 mmHg
• Flash Point: 194.5°C
• Density: 1.3g/cm³
• Vapor Pressure: 8.87E-11mmHg at 25°C
• Refractive Index: 1.595
• CAS DataBase Reference: 4-hydroxy-2,3,6-trimethoxy-5H-benzo[7]annulen-5-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-hydroxy-2,3,6-trimethoxy-5H-benzo[7]annulen-5-one(15795-64-9)
• EPA Substance Registry System: 4-hydroxy-2,3,6-trimethoxy-5H-benzo[7]annulen-5-one(15795-64-9)

Safety Data

• Hazardous Substances Data: 15795-64-9(Hazardous Substances Data)

Upstream product

• 186581-53-3 diazomethane 
• 569-77-7 purpurogallin 
• 623-11-0 1-methyl-4-nitrosobenzene 
• 77-78-1 dimethyl sulfate 
• 7647-01-0 hydrogenchloride 
• 6273-57-0 2,3,4,6-tetramethoxy-5H-benzo[7]annulen-5-one 
• 74-88-4 methyl iodide 

Downstream Products

• 569-77-7 purpurogallin 
• 4030-35-7 3,4,6-trihydroxy-2-methoxy-5H-benzo[7]annulen-5-one 
• 553-90-2 Dimethyl oxalate 
• 144-62-7 oxalic acid 
• 364764-93-2 4,2',3'-trimethyl-4'-(p-fluorobenzoyl)purpurogallin 
• 364764-92-1 4,2',3'-trimethyl-4'-benzoylpurpurogallin 
• 364764-95-4 4,2',3'-trimethyl-4'-(p-chlorobenzoyl)purpurogallin 
• 364764-96-5 4,2',3'-trimethyl-4'-(p-anisoyl)purpurogallin 
• 364764-94-3 4,2',3'-trimethyl-4'-(o-fluorobenzoyl)purpurogallin 
• 946832-61-7 4,2',3'-trimethyl-4'-(p-fluorobenzyl)purpurogallin 
• 946832-64-0 4,2',3'-trimethyl-4'-(o-fluorobenzyl)purpurogallin 
• 946832-66-2 4,2',3'-trifluoro-4'-(p-chlorobenzyl)purpurogallin 
• 946832-69-5 4,2',3'-trimethyl-4'-(p-methoxybenzyl)purpurogallin 
• 6273-57-0 2,3,4,6-tetramethoxy-5H-benzo[7]annulen-5-one 

Relevant articles and documents

-

-

Discovery of small-molecule inhibitors of the TLR1/TLR2 complex

An important regulator of innate immunity, the protein complex of Toll-like receptors 1 and 2 (TLR1/TLR2) provides an attractive target for the treatment of various immune disorders. The novel compound CU-CPT22 can compete with the binding of the specific lipoprotein ligand to TLR1/TLR2 (see picture) with high inhibitory activity and specificity. Repression of downstream signaling from TNF-α and IL-1β was also observed. Copyright